Long-term update of US GI intergroup RTOG 98-11 Phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin

Journal of Clinical Oncology

Volumn 30, Issue 35, 2012, Pages 4344-4351

  Gunderson, Leonard L ^a   Winter, Kathryn A ^b   Ajani, Jaffer A ^c   Pedersen, John E ^d   Moughan, Jennifer ^b   Benson III, Al B ^e   Thomas, Charles R ^f   Mayer, Robert J ^g   Haddock, Michael G ^h   Rich, Tyvin A ⁱ   Willett, Christopher G ^j  

^a MAYO CLINIC   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CROSS CANCER INSTITUTE   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MAYO CLINIC ROCHESTER   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ANUS CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLOSTOMY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84870733824     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.8085     Document Type: Article

References (28)

1. Nigro ND, Seydel HG, Considine B, et al: Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51:1826-1829, 1983 (Pubitemid 13093950)
2. Sischy B, Doggett RL, Krall JM, et al: Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: Interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 81:850-856, 1989 (Pubitemid 19147389)
3. Cummings BJ, Keane TJ, O'Sullivan B, et al: Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21:1115-1125, 1991
4. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14: 2527-2539, 1996 (Pubitemid 26300120)
5. [No authors listed]: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin: UKCCCR Anal Cancer Trial Working Party-UK Co-ordinating Committee on Cancer Research. Lancet 348:1049-1054, 1996
6. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997 (Pubitemid 27209535)
7. Ajani JA, Winter KA, Gunderson LL, et al: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299:1914-1921, 2008 (Pubitemid 351574921)
8. Ajani JA, Winter KA, Gunderson LL, et al: US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy. J Clin Oncol 27:1116-1121, 2009
9. Ajani JA, Winter KA, Gunderson LL, et al: Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11). Cancer 116:4007-4013, 2010
10. Allal AS, Laurencet FM, Reymond MA, et al: Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer 86:405-409, 1999 (Pubitemid 29347401)
11. Gunderson LL, Moughan J, Ajani JA, et al: Anal carcinoma: Impact of TN category of disease on survival, disease relapse and colostomy failure in US GI Intergroup RTOG 98-11 phase III trial. Int J Radiat Oncol Biol Phys 78:S55-S56, 2010 (suppl; abstr 117).
12. Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365-375, 1974
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
15. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980, pp 167-169
16. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
17. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
18. James R, Wan S, Glynne-Jones R, et al: A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol 27:170s, 2009 (suppl; abstr LBA 4009)
19. Ben-Josef E, Moughan J, Ajani JA, et al: Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 28:5061-5066, 2010
20. Bentzen SM: Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol 79:581-585, 2003
21. Fyles A, Keane TJ, Barton M, et al: The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25:273-279, 1992 (Pubitemid 23000770)
22. Maciejewski B, Majewski S: Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21:163-170, 1991
23. Glynne-Jones R, Hoskin P: Neoadjuvant cisplatin chemotherapy before chemoradiation: A flawed paradigm? J Clin Oncol 25:5281-5286, 2007 (Pubitemid 350232262)
24. Marples B, Lambin P, Skov KA, et al: Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol 71:721-735, 1997 (Pubitemid 27306027)
25. Dolling JA, Boreham DR, Brown DL, et al: Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Radiat Biol 74:61-69, 1998 (Pubitemid 28320019)
26. Kim JJ, Tannock IF: Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 5:516-525, 2005 (Pubitemid 40942828)
27. Kachnic L, Winter K, Myerson R, et al: Early efficacy results of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluououracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 78:S55, 2010 (suppl; abstr 116)
28. Ajani JA, Wang X, Izzo JG, et al: Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 55:1098-1105, 2010